This week in charts: Brain drugs are back on venture capitalists’ minds
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
Dernières en Biotech & Health Tech rss
The future of heart drug research in the wake of study setbacks
On this week’s episode of “The Readout LOUD”: the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research. Plus, drug safety concerns weigh on some of the biggest…
STAT+: Across the U.S., homegrown experiments aim to save kids from their phones
MILWAUKEE — Kat Zilka sat on the floor of her living room, beside a glowing Christmas tree and a pile of essays, and felt like weeping. It was late in 2022, and she had asked her 12th grade digital journalism students to reflect on their…
Opinion: STAT+: ‘What will I do with the time I have left?’: What it’s like to find out you might develop Alzheimer’s
This is the second of two pieces about the experiencing of pre-clinical Alzheimer’s. Read the first here . In 1976, at the dawn of the modern Alzheimer’s era, the neurologist Robert Katzman, champion of efforts to extract Alzheimer’s from…
5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry
The investigation started with a tip from a British couple. After trying to have a second child for several years, they had signed up with a U.S.-based company called International Fertility Group (IFG), paying tens of thousands of dollars…
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated. Eli Lilly…
Senator-elect Abdul El-Sayed on restoring trust in science, the state of public health, and RFK Jr.
Abdul El-Sayed will soon become the first epidemiologist in the Senate at a moment that would keep anyone with a public health background up at night. More than 5,000 Americans have been sickened by the measles this year and the United…
Windward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
A unified and practical taxonomy for false discovery rate control in omics research
Nature Biotechnology, Published online: 13 November 2026; doi:10.1038/s41587-026-03379-8 False discovery rate (FDR) control is central to omics research, yet the diverse procedures used rely on different assumptions. This Comment proposes…
Blackstone bets $1.5B on Pfizer’s obesity drug
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The song “ Donnie Darko ” by Let’s Eat Grandma was on repeat during the making of this Readout. The need-to-know…
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
STAT+: Scientists debut map of basal ganglia, a key brain region involved in an array of diseases
A massive scientific collaboration meant to unravel the mysteries of the human brain has produced the most detailed map yet of the basal ganglia, a region closely associated with a wide array of psychiatric and neurologic disorders.…
Abbott’s defibrillation lead lands FDA approval and CE mark
The authorizations position Abbott to launch a purpose-built lead for left bundle branch area pacing in the U.S. and Europe.
STAT+: Will Heidi Overton get to run the FDA?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. RFK Jr. paid tribute to the late…
J&J leads Francis Medical investment to fund prostate cancer device
With Johnson & Johnson’s support, Francis plans to take its water-vapor therapy device through the premarket approval process.
STAT+: New documents raise more questions about Medicare’s AI prior-authorization experiment
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! With…
The FDA has over 1k open jobs — and the staffing shortage is hitting pharma
The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be…
Experts update prostate cancer screening guidelines for men
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Happy Thursday. We’ve got a great lineup for you today, including an inside look at shuffles within the Senate’s health…
American Cancer Society revises guidelines, urges routine PSA screening for prostate cancer
In a major change to screening guidelines, the American Cancer Society recommended on Thursday that American men between ages 50 and 69 at an average risk of prostate cancer should test their prostate-specific antigen (PSA) blood levels…
STAT+: What to know about Biogen’s big lupus study readout
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. More than two years have passed since…
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. Accountability check: Let’s talk about…
Newly elected doctors and scientists hope to restore trust in science. It won’t be easy
Last week, doctors and scientists across the country persuaded Americans to vote them into office. Now comes the hard part: Convincing those who didn’t trust them to believe in their mission. Doctors and public health officials ran…
Opinion: I research MAHA and Black Americans. The relationship is complicated — and fascinating
When one thinks about the key supporters of MAHA, they likely don’t envision Black people, and rightfully so. A 2025 poll from KFF and The Washington Post found that only 30% of Black Americans support the MAHA movement, compared with 43%…
Opinion: 3 things new governors must do to lead on health
As former state health leaders, we know the challenges and opportunities facing the 21 new governors stepping into their roles on Jan. 1. Health is what lets people go to work, raise their kids, and enjoy the years they’ve earned. Health…
A comprehensive analysis of CBER experience with AAV gene therapy IND submissions
Nature Biotechnology, Published online: 12 November 2026; doi:10.1038/s41587-026-03378-9 An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in…
All of Us study finds thousands of new genetic variants affecting drug responses
A study of nearly 100,000 Americans identified thousands of new variants in a set of genes that influence our responses to prescription drugs, thanks to the inclusion of participants from a more diverse set of ancestries than previous…
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Thanksgiving is approaching and I’ve yet to make an all-butter pie crust that doesn’t shrink. Any…
Opinion: What MAHA’s support for Russell Brand tells us about the movement
The British comedian Russell Brand is a major figure in health secretary Robert F. Kennedy’s Make America Healthy Again movement. He regularly joined conference calls organized by the super PAC MAHA Action , on one occasion dialing in…
Oura makes bet on AI in healthcare with $625M Counsel Health buy
The planned acquisition comes as wearable firms push to up their healthcare offerings.
Drug price hikes in Germany could push US costs higher, study says
The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.
STAT+: BMI alternative would flip obesity diagnosis for millions, study finds
LONDON — Millions of people would have their obesity diagnoses flipped — from having obesity to not, and vice versa — if an alternate way of defining the disease supplanted the standard body mass index measure, according to a new study…
Danaher’s Cepheid business to lay off 67 people in California
The job cuts at Danaher’s molecular diagnostics subsidiary will take place by the end of the year and affect mostly scientists and engineers, according to a state filing.
Tandem recalls Mobi insulin pump, reports 230 adverse events
A problem with a false occlusion alarm could interrupt insulin delivery for users, according to an entry in the FDA’s recall database.
STAT+: Why this former ER doc thinks giving AI less information is sometimes better
This is the web edition of STAT’s AI Prognosis newsletter, our guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. Let me know if, especially after reading the below item…
STAT+: Cassidy sets key vote on Overton, even as he remains undecided on nominee to lead FDA
WASHINGTON — The Senate health committee has scheduled a pivotal vote for next week on the nomination of Heidi Overton to serve as commissioner of the Food and Drug Administration — despite lingering doubts from Republicans on the panel.…
STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While…
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
The U.S. may soon lose measles elimination status
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Good morning. We’re working today here at STAT. Send story ideas (I’m still on the addiction beat!), your favorite workday…
Opinion: Low-income parents can’t afford to take chances with nutritious food their picky eaters might reject
As high food costs and cuts to food assistance squeeze families’ budgets, concerns are growing about whether low-income parents will be able to keep putting food on the table. But these financial pressures threaten to do more than increase…
A new tactic in the war over out-of-network bills: Health care providers are suing employers
This past August, Joe Hancock, a Kentucky plumbing and heating contractor, opened a just-delivered box packed with hundreds of sheets of paper. Leafing through them, he read seven words no small business owner wants to see: “A lawsuit has…
STAT+: Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
WASHINGTON — Federal officials have granted blanket waivers to every member of an influential, yet little-known federal panel that evaluates preventive medical services, allowing them to serve despite some having clear financial stakes in…
STAT+: MDCalc launches a ‘rumble strip’ for doctors using generative AI tools
MDCalc , a medical reference tool site, on Wednesday launched CrossCover, a tool the company said is meant to help clinicians trust the answers of medical artificial intelligence chatbots while preserving patient and provider privacy.…
PepGen soars on promising early data for muscular dystrophy drug
While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.
The Multi-Vendor Problem in Specialty Pharma -- and Why Manufacturers Are Consolidating
The Multi-Vendor Problem in Specialty Pharma -- and Why Manufacturers Are Consolidating Multiple vendors can create bottlenecks, fragmented data, and delays in specialty pharma. Discover how a unified model can improve visibility, enable…
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
Virtuoso robot wins FDA nod for bladder tumor removal
Virtuoso Surgical’s robotic system can remove lesions in one piece in a minimally invasive procedure designed to improve cancer diagnosis and staging.
Getinge hires president of acute care therapies
Stacy Beske joins Getinge from Philips and will take over the role on Dec. 1.
London biotech Oyster harvests $60M for tau-targeting brain drugs
Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
BIO unveils plan for US to remain biotech’s ‘global leader’
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
Climate biotechnology
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03370-3 Recent patents relating to biotechnological solutions to mitigate or adapt to climate change.
Dual-layer engineering of herbicide resistance in crops
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03391-y Dual-layer engineering of herbicide resistance in crops
De novo design of proteases
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03389-6 De novo design of proteases
Biotech news from around the world
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03384-x Biotech news from around the world
Silence snapped up for $1.3 billion
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03393-w Silence snapped up for $1.3 billion
Searching perturbation dictionaries with RNA fingerprints
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03390-z Searching perturbation dictionaries with RNA fingerprints
UK Biobank adds immune and brain health layers
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03388-7 UK Biobank adds immune and brain health layers
China plans ban on biotech exports
Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03397-6 China plans ban on biotech exports
Bayer wins FDA nod for a new kind of blood thinner
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
Labcorp completes $375M Millennium Health takeover
The deal, which includes a $245 million upfront fee, expands the geographic reach of Labcorp’s drug testing business.
Vir hepatitis D drug succeeds in first pivotal study
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
Novocure denied FDA approval for metastatic cancer treatment
The FDA had uncertainty about the degree of clinical benefit for Novocure’s treatment of brain metastases, the company said.
Argenx to buy peptide platform in potentially billion-dollar deal
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
FDA seeks input on telesurgery, autonomous robotics
The agency is inviting public comment on a new discussion paper as it prepares to shape policy covering robotic medical devices with autonomous or remote teleoperation functions.
Ramaswamy’s biotech baggage haunted his political run
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
Making the ‘impossible’ executable in life sciences construction
Why early technical expertise matters when complex life sciences projects challenge convention.
Translating Phase II success into Phase III readiness takes more than scale
The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.
State incentives for commercial-stage life sciences companies
Factor incentives into expansion plans early to improve site decisions, manage commitments and free capital for what comes next.
Find opportunity in a shifting life sciences market
See where capital and deal activity are moving, with insights to inform stronger investment, growth and strategic decisions.
Natera promotes Solomon Moshkevich to CEO
The CEO change was unexpected and prompted a stock selloff Friday, analysts said, but the new chief executive is prepared for the role.
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”
Tandem Diabetes Care names next CEO
Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019.
Medicare will cut billions from 340B, expand site-neutral payments in 2027
Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some payments between care sites. Hospitals railed against the rule.